alexa The Achilles Heel of Cervical Cancer: An Overlooked Target? | OMICS International
ISSN: 2153-0645
Journal of Pharmacogenomics & Pharmacoproteomics

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Achilles Heel of Cervical Cancer: An Overlooked Target?

Alfonso Dueñas-Gonzalez*

Unit of Biomedical Research on Cancer, Institute of Biomedical Research, National Autonomous University of Mexico/National Cancer Institute, Mexico

*Corresponding Author:
Alfonso Dueñas-Gonzalez
Unit of Biomedical Research on Cancer
Institute of Biomedical Research
National Autonomous University of Mexico/National Cancer Institute
San Fernando 22, Tlalpan 14080, Mexico
Tel: +5255 54853034
E-mail: [email protected]

Received date: October 22, 2012; Accepted date: October 23, 2012; Published date: October 27, 2012

Citation: Dueñas-Gonzalez A (2012) The Achilles Heel of Cervical Cancer: An Overlooked Target? J Pharmacogenomics Pharmacoproteomics 3:e128. doi: 10.4172/2153-0645.1000e128

Copyright: © 2012 Dueñas-Gonzalez A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pharmacogenomics & Pharmacoproteomics

Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer death in females, accounting for 9% (529,800) of total new cancer cases and 8% (275,100) of total cancer deaths among females in 2008. This cancer mainly affects socially disadvantaged women; hence, it is much more common in developing countries, where 83% of cases occur [1]. Despite these figures, there is a shortage of novel therapeutical agents for invasive cervical cancer in late stages of development.

In the current paradigm of molecular targeted therapy, cervical cancer has -though not in the extension to common solid neoplasias such as breast, lung and colon- being subjected to exploration with whole genome and proteome tools to get a better understanding of its biology and hopefully to develop novel methods of diagnosis and treatment. A comprehensive genetic landscape analysis for cervical cancer has yet to be performed. Though preliminary, information from the Sanger data base [2] shows that the mutation frequencies in primary cervical cancer are: BRCA2 (8%), FBXW7 (8%), K-RAS (8%), MSH2 (8%), PI3KA (31%), PTEN (8%), RB1 (8%), STK11 (23%) and TP53 (23%). These figures suggest that cervical cancer has not a high frequency of targetable gene alteration that could be translated into an effective treatment at to the present status of available drugs. More comprehensive studies are needed, however, the lessons we can take from whole genome sequencing of tumors are that most cancer types display substantial heterogeneity at the genetic level. For instances, individual solid organ tumors harbor on average >50 no silent clonal mutations in the coding regions of different genes (colorectal = breast >> pancreatic > glioblastoma multiforme), and although a few of these genes are mutated in a high proportion of tumors, the prevalence at which the majority are mutated among different tumors of the same cancer type is low [3]. With the ever-increasing recognition that so-called “junk” DNA and intronic sequences contain functional elements, including regulatory regions and non coding RNAs, as revealed by The ENCODE Project Consortium [4] the total number of genomic alterations with functional consequences cannot be easily estimated. This underlies the complexity of the cancer genome landscape that confounds many of the original expectations of the cancer genome strategy. Thus, the future of personalized medicine concept where targeted therapies concurrent or sequential are to be administered based on patient stratification looks less hopeful than initially anticipated.

These by no means suggest that efforts toward an effective personalized medicine using targeted agents should not be continued but “common-sense driven or educated guess” approach need not to be overlooked. In this line, it is remarkable that Human Papilloma Virus (HPV) has long be established as the etiology of cervical cancer (and other neoplasias) by the regular presence of HPV DNA and their E6/ E7 viral oncogenes expression [5]. Of utmost importance are the solid evidence that cervical cancer cells require the expression of these viral oncogenes for maintaining the malignant phenotype via interaction of viral oncoproteins with growth-regulating host-cell proteins [6- 10], thus, essentially, HPV oncoproteins directly or indirectly exert oncogenic effects upon cancer hallmarks [7], i) resisting cell death, ii) inducing angiogenesis, iii) sustaining proliferative signaling, iv) evading growth suppressors, v) activating invasion and metastasis, vi) and enabling replicative immortality.

The most compelling evidence on the key role of HPV oncoproteins in cervical cancer is the demonstration that repressing endogenous HPV oncogenes (E6/E7) mobilizes the p53 and Rb pathways in an orderly fashion to deliver growth inhibitory signals to the cells, hence unlike most cancers, in which the brakes on cell growth are broken, in HeLa cells -which are reminiscent of a advanced cervical cancer [11]- the driver is asleep, hence, down-regulation of E6/E7 is sufficient to wake up the driver and impose growth control [12]. This has subsequently being confirmed using a variety of nucleic acid-based [13-15] or small molecule approaches [16,17]. Nevertheless, despite the strong rationale of using anti-HPV targeted agents, clinical development of these agents against invasive cervical cancer is almost none.

Is there any scientific reason why to overlook HPV-oncoproteins as the long-searched therapeutic targets for invasive cervical cancer? Overlook means “to ignore deliberately or indulgently” Has it anything to do with the fact that current markets primarily drive the model of drug development? The question is open but it must be acknowledged that even though it is estimated that cervical cancer will decrease by 4% between 2010 and 2020 in seven major markets, 35,898 women will still develop cervical cancer in these countries.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • International Conference And Exhibition on Drug Safety & Pharmacovigilance
    August 29-30, 2018 Toronto, Canada
  • 18th World Pharma Congress
    October 18-19, 2018 Warsaw, Poland

Article Usage

  • Total views: 11820
  • [From(publication date):
    December-2012 - Jul 19, 2018]
  • Breakdown by view type
  • HTML page views : 8034
  • PDF downloads : 3786

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7